SavedAdd your journal

Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 12

miRNA expression profile in Behcet patients using colchicine

Nilnur EYERCİ
Necmettin AKDENİZ
Sadullah KELEŞ
Eda BALKAN
Pages
3159–3165
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, patients in the active period also require further studies to fully understand the role and mechanism of action of the drug.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Behcet’s disease (BD) is a multi-systemic disorder which shows inflammatory vasculitis characteristic with recurrent oral aphthae, eye lesions, and genital ulceration.
📊
Key Findings & Data:We aimed to determine miRNAs that are thought to be associated with inflammatory processes in BD patients using colchicine in the active period.Materials and Methods: We enrolled 24 patients with BD receiving colchicine treatment and a control group comprising 30 healthy unrelated individuals.
💡
Conclusion & Impact:However, patients in the active period also require further studies to fully understand the role and mechanism of action of the drug.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Behcet’s disease (BD) is a multi-systemic disorder which shows inflammatory vasculitis characteristic with recurrent oral aphthae, eye lesions, and genital ulceration. MicroRNA’s (miRNAs) are small non-coding RNA molecules that play an important role in the regulation of various biological processes. We aimed to determine miRNAs that are thought to be associated with inflammatory processes in BD patients using colchicine in the active period.Materials and Methods: We enrolled 24 patients with BD receiving colchicine treatment and a control group comprising 30 healthy unrelated individuals. We studied with a panel where 377 miRNAs were included in the assay.Results: miR-20a, miR-34a, miR-197, U6snRNA, miR-205, miR-222, miR-296, miR-302a, miR-302c, and miR-372 were observed up-regulated in BD. miR-518b, miR-874 were found down-regulated within the patients. These miRNAs are known to play a role in cancer-related pathways.Conclusion: In patients treated with colchicine, the change in the expression of these miRNA may give an idea of the effect on the progression of the disease. However, patients in the active period also require further studies to fully understand the role and mechanism of action of the drug.

🔖

Cite This Article

EYERCİ, N., AKDENİZ, N., KELEŞ, S., BALKAN, E. (2022). miRNA expression profile in Behcet patients using colchicine. Annals of Medical Research, Cilt: 27 - Sayı: 12, 3159–3165. https://ajindex.com/articles/446381

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. International Team for the Revision of the International Criteria for Behcet's D. The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology: JEADV 2014;28:338- 47
  2. Salmaninejad A, Gowhari A, Hosseini S, et al. Genetics and immunodysfunction underlying Behcet's disease and immunomodulant treatment approaches. J Immunotoxicol 2017;14:137-51
  3. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Current opinion in rheumatology. 2005;17:586-99
  4. Woo MY, Cho O, Lee MJ, et al. Differential effects of colchicine in blood mononuclear cells of patients with Behcet disease in relation to colchicine responsiveness. Br J Dermatol 2012;167:914-21
  5. Aktulga E, Altac M, Muftuoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980;65:399-402
  6. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Semin Arthritis Rheum 2001;44:2686-92
  7. Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behcet's syndrome. Semin Arthritis Rheum 2019;48:752-62
  8. Chia EW, Grainger R, Harper JL. Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008;153:1288-95
  9. Li Z, Davis GS, Mohr C, et al. Inhibition of LPSinduced tumor necrosis factor-alpha production by colchicine and other microtubule disrupting drugs. Immunobiology 1996;195:624-39
  10. Slobodnick A, Shah B, Krasnokutsky S, et al. Update on colchicine, 2017. Rheumatology. 2018;57:4-11
  11. Mehta A, Baltimore D. MicroRNAs as regulatory elements in immune system logic. Nat Rev Immunol 2016;16:279-94
  12. Long H, Wang X, Chen Y, et al. Dysregulation of microRNAs in autoimmune diseases: Pathogenesis, biomarkers and potential therapeutic targets. Cancer Lett 2018;428:90-103
  13. Garo LP, Murugaiyan G. Contribution of MicroRNAs to autoimmune diseases. Cellular and molecular life sciences: CMLS 2016;73:2041-51
  14. Erre GL, Piga M, Carru C, et al. Global microRNA profiling of peripheral blood mononuclear cells in patients with Behcet's disease. Clin Exp Rheumatol 2015;33:9-72
  15. Ibrahim W, Sakr BR, Obaya E, et